Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

COMPLETED

NCT06044740

EARLY_PHASE1

Sevoflurane's Effect on Neurocognition Study

Sponsor: Keith M Vogt

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the effects of acute pain on long-term memory and conditioned physiologic responses in the presence and absence of low dose sevoflurane. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena. The study will occur over 2 visits and involves no long-term follow up.

Key Details

Gender

All

Age Range

18 Years - 59 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2024-01-17

Completion Date

2026-01-30

Last Updated

2026-04-15

Healthy Volunteers

Yes

Conditions

Anesthesia Pain Amnesia

Interventions

DRUG

Sevoflurane

After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration of 0.4% (corresponding to 0.2 Minimum Alveolar Concentration) is reached.

DEVICE

Peripheral Nerve Stimulation

Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.

Inclusion Criteria: * Adults, age 18-59, who are native English speakers with at least a high school education * have normal hearing and memory * be of normal body-weight * be generally healthy (free from significant chronic disease) * have none of the specific exclusion criteria * have a valid email address and valid phone number throughout the study * anticipate ability to participate in all visits required for the phase of the study in which they are enrolled Exclusion Criteria: * being pregnant or attempting to conceive * having a body mass index (BMI) \> 35 * having significant memory impairment or hearing loss * having sleep apnea * having chronic pain or frequently taking pain medication (including tramadol) * having any severe or poorly-controlled medical problem (hypertension, diabetes) * having neurologic or psychiatric disease, including anxiety, and depression * having significant cardiac valvular disease or cardiomyopathy * having a history of abnormal heartbeats (cardiac conduction abnormality or arrhythmia) * having a history of seizures or convulsions * having a history of liver disease * having a history of asthma or other significant pulmonary disease * having a history of malignant hyperthermia, muscular dystrophy, central core disease, or hyperkalemia * being claustrophobic * have metal implants or non-removable metal piercings * having a history of adverse reaction to anesthetics * daily alcohol or heavy alcohol use; history of alcohol abuse * current daily smoker * regular or recent marijuana use (including prescribed/medical marijuana) * illicit drug use * regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids * current use of selective serotonin reuptake inhibitors (SSRIs), noradrenaline reuptake inhibitors (SNRIs), or monoamine oxidase inhibitors (MAOIs) and some other specific drugs phenytoin, carbamazepine, and rifampin * history of QT prolongation * hypersensitivity or allergic reaction to ondansetron (Zofran)

Locations (1)

University of Pittsburgh

Pittsburgh, Pennsylvania, United States